fashion -WSS

fashion

author：leisure time 2025-09-04 04:43:28 - browse：949

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Beam Therapeutics to lay off 20% of its staff, re

WSS

Interest rates are at a 22

CEOs share strategies for surviving biotech slump

NIH confirmation hearing shows politicization of research

CEOs share strategies for surviving biotech slump

First Opinion Podcast: Long Covid needs a new approach

Marc Tessier

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

Hospitals, health systems can help patients avoid medical debt

23andMe had bad news about my health. I wish a person had delivered it

Solve the antibiotic resistance crisis with preventive drugs

Hollywood unions extend contract negotiations for actors

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

Novavax promises a turnaround & Lilly roils the obesity market

Interest rates are at a 22

Medicare proposal to cover medical devices draws a mixed reaction

'The boss' wants server deleted: New allegations emerge in Trump indictment

focus

UnitedHealth’s board chair also owns a personal investment firm

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Stoke drug shows lower activity against childhood epilepsy

CDC: Cases of alpha

Stoke drug shows lower activity against childhood epilepsy

explore

focus

hotspot

focus